Table 2.
Multivariate analysis of factors associated with worsening CT score in RA-ILD patients.
| Variable | Worsening (n=18) |
Not Worsening (n=75) |
P Value | Multivariate Hazard Ratio (95% Confidence Interval) |
P Value |
|---|---|---|---|---|---|
| Treatment | 0.87 | ||||
| JAKi, n | 7 | 29 | |||
| CTLA4-Ig, n | 5 | 25 | |||
| TNFi, n | 6 | 21 | |||
| Gender | 0.10 | 3.76 (1.05–13.52) | 0.043 | ||
| Female/Male, n | 15/3 | 46/29 | |||
| Age | 0.12 | 2.15 (0.69–6.69) | 0.19 | ||
| ≥75/<75 years, n | 10/8 | 26/49 | |||
| RA Onset Age | 0.059 | 1.32 (0.43–4.05) | 0.63 | ||
| ≥65/<65 years, n | 11/7 | 26/49 | |||
| RA Duration | 0.80 | ||||
| ≥10 years/<10 years, n | 9/9 | 34/41 | |||
| RF Status | 0.58 | ||||
| Positive/Negative, n | 18/0 | 70/5 | |||
| ACPA Status | 0.35 | ||||
| Positive/Negative, n | 18/0 | 67/8 | |||
| Concomitant Use of MTX | 0.013 | 0.19 (0.03–1.08) | 0.061 | ||
| Yes/No, n | 2/16 | 33/42 | |||
| Concomitant Use of GC | 0.43 | ||||
| Yes/No, n | 8/10 | 43/32 | |||
| DAS28-ESR | 0.61 | ||||
| High disease activity, n | 6 | 30 | |||
| Moderate disease activity, n | 7 | 37 | |||
| Low disease activity, n | 1 | 4 | |||
| Remission, n | 2 | 3 | |||
| CT Pattern | 0.58 | ||||
| UIP/non-UIP, n | 7/11 | 23/52 | |||
| Extent of Fibrotic Lesions | 0.0040 | 3.51 (1.28–9.63) | 0.015 | ||
| >10%/≤10%, n | 9/9 | 12/63 |
ACPA, anti-citrullinated protein antibody; CT, computed tomography; CTLA4-Ig, T cell co-stimulation inhibitor; DAS28-ESR, Disease Activity Score based on a 28-joint count–erythrocyte sedimentation rate; GC, glucocorticoids; ILD, interstitial lung disease; IQR, interquartile range; JAKi, Janus kinase inhibitor; MTX, methotrexate; RA, rheumatoid arthritis; RF, rheumatoid factor; TNFi, tumor necrosis factor inhibitor; UIP, usual interstitial pneumonia.